Abstract
Introduction: Excessive body weight gain (BWG), hyperglycemia and dyslipidemia are important side
effects of olanzapine. We assessed the effects of rosiglitazone on BWG, the insulin
resistance index (HOMA-IR), lipids, glycated hemoglobin and fibrinogen in olanzapine-treated
schizophrenia patients.
Methods: Thirty patients taking olanzapine (10–20 mg daily for 8 months) were randomly allocated
to rosiglitazone (n=15; 4 to 8 mg daily) or placebo (n=15) in a 12-week double-blind
protocol. Anthropometric and biochemical variables were evaluated at baseline, weeks
6 and 12.
Results: The rosiglitazone and placebo groups gained 3.2±4.5 and 2.2±2.3 kg, respectively
(p=0.65). Insulin and the HOMA-IR significantly decreased after rosiglitazone (p<0.05).
Rosiglitazone did not improve the lipid profile, fibrinogen and Hb1c levels.
Discussion: The positive impact of rosiglitazone was limited to improved glycemic control. It
cannot be recommended for metabolic control during olanzapine treatment.
References
1
Ader M, Kim SP, Catalana KJ.
Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying
disease: a placebo-controlled study of olanzapine and risperidone in dogs.
Diabetes.
2005;
54
862-871
2
Baptista T, Zarate J, Joober R. et al .
Drug-induced weight gain: an impediment for successful pharmacotherapy: focus on antipsychotics.
Curr Drug Targ.
2004;
5
279-299
3
Baptista T, Martinez J, Lacruz A. et al .
Metformin for prevention of weight gain and insulin resistance with olanzapine: a
double-blind placebo-controlled trial.
Can J Psychiatry.
2006;
51
192-196
4
Baptista T, Rangel N, Fernandez V. et al .
Metformin as an adjunctive treatment to control body weight and metabolic dysfunction
during olanzapine administration: a multicentric, double-blind, placebo-controlled
study.
Schizophr Res.
2007;
93
99-108
5
Centorrino F, Wurtman JJ, Duca KA. et al .
Weight loss in overweight patients maintained on atypical antipsychotic agents.
Int J Obes (Lond).
2006;
30
1011-1016
6
Chen CH, Chiu CC, Huang MC. et al .
Metformin for metabolic dysregulation in schizophrenic patients treated with olanzapine.
Prog Neuropsychopharmacol Biol Psychiatry.
2007;
, Nov 17 (Epub ahead of print)
7
Hert M De, Kalnicka D, Winkel R Van. et al .
Treatment with rosuvastatin for severe dyslipidemia in patients with schizophrenia
and schizoaffective disorder.
J Clin Psychiatry.
2006;
67
1889-1896
8
Faulkner G, Cohn T, Remington G.
Interventions to reduce weight gain in schizophrenia.
Cochrane Database Syst Rev.
2007;
24
CD005148
9
Festa A, D’Agostino Jr R, Mykkanen L. et al .
Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large
population with different states of glucose tolerance: the Insulin Resistance Atherosclerosis
Study (IRAS).
Arterioscler Thromb Vasc Biol.
1999;
19
562-568
10
Gentile S.
Long-term treatment with atypical antipsychotics and the risk of weight gain: a literature
analysis.
Drug Saf.
2006;
29
303-319
11
Goldberg RB, Kendall DM, Deeg MA. et al .
A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients
with type 2 diabetes and dyslipidemia.
Diabetes Care.
2005;
28
1547-1554
12
Goldberg RB.
Impact of thiazolidenediones on serum lipoprotein levels.
Atheroscler Rep.
2006;
8
397-404
13
Haffner S, Temprosa M, Crandall J. et al .
Intensive lifestyle intervention or metformin on inflammation and coagulation in participants
with impaired glucose tolerance.
Diabetes.
2005;
54
1566-1572
14
Hermansen K, Mortensen LS.
Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus.
Drug Saf.
2007;
30
1127-1142
15
Houseknecht KL, Robertson AS, Zavadoski W. et al .
Acute effects of atypical antipsychotics on whole-body insulin resistance in rats:
implications for adverse metabolic effects.
Neuropsychopharmacology.
2007;
32
289-297
16
Isley WL.
Hepatotoxicity of thiazolidinediones.
Expert Opin Drug Saf.
2003;
2
581-586
17
Klein DJ, Cottingham EM, Sorter M. et al .
A randomized, double-blind, placebo-controlled trial of metform in treatment of weight
gain associated with initiation of atypical antipsychotic therapy in children and
adolescents.
Am J Psychiatry.
2006;
163
2072-2079
18
Lieberman JA, Stroup TS, MacEvoy JP. et al .
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
N Engl J Med.
2005;
353
1209-1223
19
Matthews DR, Hosker JP, Rudenski AS. et al .
Homeostasis model assessment: insulin resistance and beta-cell function from fasting
plasma glucose and insulin concentrations in man.
Diabetologia.
1985;
28
412-419
20
MacIntyre RS, Soczynska JK, Lewis GF. et al .
Managing psychiatric disorders with antidiabetic agents: translational research and
treatment opportunities.
Expert Opin Pharmacother.
2006;
7
1305-1321
21
Menza M, Vreeland B, Minsky S. et al .
Managing atypical antipsychotic-associated weight gain: 12-month data on a multimodal
weight control program.
J Clin Psychiatry.
2004;
65
471-477
22
Newcomer J.
Medical risk in patients with bipolar disorder and schizophrenia.
J Clin Psychiatry.
2006;
67
((Suppl 9))
25-30
23
Newcomer J.
Metabolic considerations in the use of antipsychotic medications: a review of recent
evidence.
J Clin Psychiatry.
2007;
68
((Suppl 1))
20-27
24
Nissen SE, Wolski K.
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular
causes.
N Engl J Med.
2007;
356
2457-2471
25
Sarafidis PA, Bakris GL.
Protection of the kidney by thiazolidinediones: an assessment from bench to bedside.
Kidney Int.
2006;
70
1223-1233
26
Sarafidis PA, Nilsson PM.
The effects of thiazolidinediones on blood pressure levels – a systematic review.
Blood Press.
2006;
15
135-150
27
Schaefer M, Leopold K, Hinzpeter A. et al .
Memantine-associated reversal of clozapine-induced weight gain.
Pharmacopsychiatry.
2006;
39
171-174
28
Scheen AJ.
Pharmacokinetic interactions with thiazolidinediones.
Clin Pharmacokinet.
2007;
46
1-12
29
Slama G, Eschwege E, Bernard MH. et al .
One-year follow-up in real clinical practice conditions of type 2 diabetic patients
treated with rosiglitazone: The Avantage study.
Ann Endocrinol (Paris).
Date: 2008 Feb 1;
, [in press]
30
Sowell MO, Mukhopadhyay N, Cavazzoni P. et al .
Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated
with olanzapine, risperidone, or placebo.
Clin Endocrinol Metab.
2002;
87
2918-2923
31
Spitzer RL, Williams JBW, Gibbon M. et al .
The Structured Clinical Interview for DSM-III-R (SCID), I: history, rationale, and
description.
Arch Gen Psychiatry.
1992;
49
624-429
32
Vasudevan AR, Balasubramanyam A.
Thiazolidinediones: a review of their mechanisms of insulin sensitization, therapeutic
potential, clinical efficacy, and tolerability.
Diabetes Technol Ther.
2004;
6
850-863
33
Wellington K.
Rosiglitazone/metformin.
Drugs.
2005;
65
1581-1592
34
Wu RR, Zhao JP, Guo XF. et al .
Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode
schizophrenia patients: a double-blind, placebo-controlled study.
Am J Psychiatry.
Date: 2008 Feb 1;
, (Epub ahead of print)
35
Yilmaz H, Gursoy A, Sahin M. et al .
Comparison of insulin monotherapy and combination therapy with insulin and metformin
or insulin and rosiglitazone or insulin and acarbose in type 2 diabetes.
Acta Diabetol.
2007;
44
187-192
Correspondence
Prof. T. BaptistaMD, PhD
Department of Physiology
Los Andes University Medical School
P.O. Box 93
Mérida 5101-A
Venezuela
Telefon: +58/274/240 31 10
Fax: +58/274/263 63 95
eMail: trinbap@yahoo.com